首页 > 最新文献

American Journal of Hypertension最新文献

英文 中文
High Blood Pressure Is Associated With Lower Brain Volume and Cortical Thickness in Healthy Young Adults. 高血压与健康年轻人脑容量和皮质厚度降低有关。
IF 3.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-16 DOI: 10.1093/ajh/hpae077
Junyeon Won, John Ashley, Danilo Cardim, Wanpen Vongpatanasin, Rong Zhang

Background: High blood pressure (BP) in middle-aged and older adults is associated with lower brain volume and cortical thickness assessed with structural magnetic resonance imaging (MRI). However, little evidence is available on young adults. We investigated the associations of high BP with brain volumes and cortical thickness in healthy young adults.

Methods: This cross-sectional study included 1,095 young adults (54% women, 22-37 years) from the Human Connectome Project (HCP) who self-reported not having a history of hypertension or taking antihypertensive medications. Brachial systolic (SBP) and diastolic BP (DBP) were measured with a semi-automatic or manual sphygmomanometer during study visits. Structural MRI was used to measure gray matter (GM) and white matter (WM) volume and mean cortical thickness. Associations of BP and hypertension stage with total and regional brain volumes and cortical thickness were analyzed using linear regression and analysis of covariance (ANCOVA) after adjusting for age, sex, education years, body mass index (BMI), smoking, alcohol consumption history, zygosity, and total intracranial volume.

Results: SBP and DBP were (mean ± SD) 123.6 ± 14.2 and 76.5 ± 10.6 mm Hg, respectively, (n = 1,095). High DBP was associated with lower total GM (P = 0.012), cortical GM (P = 0.004), subcortical GM (P = 0.012), and total WM volumes (P = 0.031). High SBP and DBP were associated with lower regional cortical volume and cortical thickness.

Conclusions: These findings suggest that high BP may have deleterious effects on brain health at the early stage of adulthood.

背景:中老年人的高血压(BP)与结构磁共振成像评估的脑容量和皮质厚度降低有关。然而,很少有证据表明年轻人也会出现这种情况。我们研究了健康年轻人的高血压与脑容量和皮层厚度的关系:这项横断面研究纳入了人类连接组项目(HCP)中的 1095 名年轻人(54% 为女性,22-37 岁),他们自称没有高血压病史或正在服用降压药。研究访问期间使用半自动或手动血压计测量肱动脉收缩压(SBP)和舒张压(DBP)。结构性核磁共振成像用于测量灰质(GM)和白质(WM)体积以及平均皮质厚度。在对年龄、性别、受教育年限、体重指数(BMI)、吸烟、饮酒史、智商和颅内总容积进行调整后,采用线性回归和协方差分析法(ANCOVA)分析了血压和高血压分期与大脑总容积、区域容积和皮层厚度的关系:SBP和DBP分别为(平均值±标准差)123.6±14.2毫米汞柱和76.5±10.6毫米汞柱(n = 1095)。高 DBP 与较低的总 GM(p = 0.012)、皮质 GM(p = 0.004)、皮质下 GM(p = 0.012)和总 WM 容量(p = 0.031)相关。高SBP和DBP与较低的区域皮质体积和皮质厚度有关:这些研究结果表明,高血压可能会在成年早期对大脑健康产生有害影响。
{"title":"High Blood Pressure Is Associated With Lower Brain Volume and Cortical Thickness in Healthy Young Adults.","authors":"Junyeon Won, John Ashley, Danilo Cardim, Wanpen Vongpatanasin, Rong Zhang","doi":"10.1093/ajh/hpae077","DOIUrl":"10.1093/ajh/hpae077","url":null,"abstract":"<p><strong>Background: </strong>High blood pressure (BP) in middle-aged and older adults is associated with lower brain volume and cortical thickness assessed with structural magnetic resonance imaging (MRI). However, little evidence is available on young adults. We investigated the associations of high BP with brain volumes and cortical thickness in healthy young adults.</p><p><strong>Methods: </strong>This cross-sectional study included 1,095 young adults (54% women, 22-37 years) from the Human Connectome Project (HCP) who self-reported not having a history of hypertension or taking antihypertensive medications. Brachial systolic (SBP) and diastolic BP (DBP) were measured with a semi-automatic or manual sphygmomanometer during study visits. Structural MRI was used to measure gray matter (GM) and white matter (WM) volume and mean cortical thickness. Associations of BP and hypertension stage with total and regional brain volumes and cortical thickness were analyzed using linear regression and analysis of covariance (ANCOVA) after adjusting for age, sex, education years, body mass index (BMI), smoking, alcohol consumption history, zygosity, and total intracranial volume.</p><p><strong>Results: </strong>SBP and DBP were (mean ± SD) 123.6 ± 14.2 and 76.5 ± 10.6 mm Hg, respectively, (n = 1,095). High DBP was associated with lower total GM (P = 0.012), cortical GM (P = 0.004), subcortical GM (P = 0.012), and total WM volumes (P = 0.031). High SBP and DBP were associated with lower regional cortical volume and cortical thickness.</p><p><strong>Conclusions: </strong>These findings suggest that high BP may have deleterious effects on brain health at the early stage of adulthood.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"792-800"},"PeriodicalIF":3.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolving the Role of Black Race in Hypertension Therapeutics. 黑人种族在高血压治疗中的作用不断发展。
IF 3.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-16 DOI: 10.1093/ajh/hpae093
John M Flack, Stephanie Bitner, Michael Buhnerkempe

Black race has been used to guide antihypertensive drug selection for Black patients based on predominant between race (same drug) and intra-race (different drugs) blood pressure (BP) response patterns. Accordingly, thiazide diuretics and calcium antagonists have been recommended over renin-angiotensin system (RAS) inhibitors (angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors) and beta blockers for Black patients. Current antihypertensive drug prescribing reflects historical guidance as calcium antagonists and thiazide diuretics are prescribed more and RAS blockers less in Black than White patients. Hypertension control rates in Blacks, lag those for Whites despite their greater use of combination drug therapy and lesser use of monotherapy. This is also true across drug regimens containing any of the 4 recommended classes for initial therapy as well as for evidence-based combination drug therapy (calcium antagonist or thiazide diuretic + RAS blocker) regimens for which there is no known racial disparity in BP response. Current recommendations acknowledge the need for combination drug therapy in most, especially in Black patients. One exemplary comprehensive hypertension control program achieved >80% control rates in Black and White patients with minimal racial disparity while utilizing a race-agnostic therapeutic algorithm. Black patients manifest robust, if not outsized, BP responses to diet/lifestyle modifications. Importantly, race neither appears to be a necessary nor sufficient consideration for the selection of effective drug therapy. Accordingly, we urge the initiation of adequately intense race-agnostic drug therapy coupled with greater emphasis on diet/lifestyle modifications for Black patients as the cornerstone of a race-informed approach to hypertension therapeutics.

根据种族间(相同药物)和种族内(不同药物)的主要血压反应模式,黑人种族被用来指导黑人患者的降压药物选择。因此,对黑人患者推荐使用噻嗪类利尿剂和钙拮抗剂,而不是肾素血管紧张素系统(RAS)抑制剂(血管紧张素受体阻滞剂、血管紧张素转换酶抑制剂)和β受体阻滞剂。目前的降压药物处方反映了历史指导,因为黑人患者比白人患者使用钙离子拮抗剂和噻嗪类利尿剂较多,而使用 RAS 阻滞剂较少。黑人的高血压控制率落后于白人,尽管他们更多地使用联合药物疗法,而较少使用单一疗法。这种情况同样适用于包含四类推荐药物中任何一类药物的初始治疗方案,以及基于证据的联合用药治疗方案(钙拮抗剂或噻嗪类利尿剂 + RAS 阻断剂),在这些方案中,血压反应没有已知的种族差异。目前的建议承认大多数患者,尤其是黑人患者需要联合用药治疗。一项示范性综合高血压控制计划在黑人和白人患者中的控制率达到了 80% 以上,种族差异极小,同时采用了种族诊断治疗算法。黑人患者对饮食/生活方式的调整表现出强劲的血压反应,甚至超常。重要的是,种族似乎既不是选择有效药物治疗的必要考虑因素,也不是充分考虑因素。因此,我们呼吁在对黑人患者进行充分密集的种族定向药物治疗的同时,更加重视饮食/生活方式的调整,以此作为高血压种族定向治疗方法的基石。
{"title":"Evolving the Role of Black Race in Hypertension Therapeutics.","authors":"John M Flack, Stephanie Bitner, Michael Buhnerkempe","doi":"10.1093/ajh/hpae093","DOIUrl":"10.1093/ajh/hpae093","url":null,"abstract":"<p><p>Black race has been used to guide antihypertensive drug selection for Black patients based on predominant between race (same drug) and intra-race (different drugs) blood pressure (BP) response patterns. Accordingly, thiazide diuretics and calcium antagonists have been recommended over renin-angiotensin system (RAS) inhibitors (angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors) and beta blockers for Black patients. Current antihypertensive drug prescribing reflects historical guidance as calcium antagonists and thiazide diuretics are prescribed more and RAS blockers less in Black than White patients. Hypertension control rates in Blacks, lag those for Whites despite their greater use of combination drug therapy and lesser use of monotherapy. This is also true across drug regimens containing any of the 4 recommended classes for initial therapy as well as for evidence-based combination drug therapy (calcium antagonist or thiazide diuretic + RAS blocker) regimens for which there is no known racial disparity in BP response. Current recommendations acknowledge the need for combination drug therapy in most, especially in Black patients. One exemplary comprehensive hypertension control program achieved >80% control rates in Black and White patients with minimal racial disparity while utilizing a race-agnostic therapeutic algorithm. Black patients manifest robust, if not outsized, BP responses to diet/lifestyle modifications. Importantly, race neither appears to be a necessary nor sufficient consideration for the selection of effective drug therapy. Accordingly, we urge the initiation of adequately intense race-agnostic drug therapy coupled with greater emphasis on diet/lifestyle modifications for Black patients as the cornerstone of a race-informed approach to hypertension therapeutics.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"739-744"},"PeriodicalIF":3.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Habitual Regular Coffee Consumption and Arterial Stiffness: Data From the 3rd Pamela Survey. 习惯性常饮咖啡与动脉硬化--来自第三次帕梅拉调查的数据。
IF 3.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-16 DOI: 10.1093/ajh/hpae072
Raffaella Dell'Oro, Fosca Quarti-Trevano, Rita Facchetti, Cesare Cuspidi, Giuseppe Mancia, Guido Grassi

Background: We evaluated whether chronic coffee consumption affects arterial stiffness, assessed by cardio-ankle vascular index (CAVI).

Methods: In 514 subjects, aged 66.6 ± 9.9 years (mean ± SD), recruited in the 3rd follow-up of the PAMELA study, subdivided into 3 groups according to the daily intake of regular coffee (0, 1-2, and ≥3 cups/day), we measured CAVI and clinic, ambulatory blood pressure (BP), and other variables.

Results: The 3 groups displayed similar age, gender, metabolic, and renal profile. Clinic and ambulatory BPs were similar in the 3 groups, this being the case for CAVI (0 cup: 9.1 ± 1.8, 1-2 cups: 9.5 ± 2.3, and ≥3 cups: 9.2 ± 2.1 m/s, P = NS). No significant gender difference in CAVI and in participants under antihypertensive treatment was detected.

Conclusions: Our data show that chronic coffee consumption leaves unaffected arterial stiffness in the general population, this being the case in subgroups. The neutral vascular impact of coffee may favor the absence of any significant BP effect of habitual coffee intake.

背景:我们评估了长期饮用咖啡是否会影响动脉僵化(用心血管指数评估):我们评估了长期饮用咖啡是否会影响动脉僵化,动脉僵化可通过心踝关节血管指数(CAVI)进行评估:在 PAMELA 研究的第三次随访中,我们招募了 514 名年龄为 66.6±9.9 岁(平均值±SD)的受试者,根据每日普通咖啡摄入量(0 杯、1-2 杯和≥3 杯/天)分为 3 组,测量了 CAVI 和门诊、门诊血压(BP)及其他变量:结果:三组患者的年龄、性别、代谢和肾脏状况相似。3 组患者的门诊血压和动态血压相似,CAVI 也是如此(0 杯:9.1±1.8,1-2 杯:9.5±2.3,≥3 杯:9.2±2.1 米/秒,P=NS)。结论:我们的数据显示,长期饮用咖啡不会影响普通人群的动脉僵化,在亚群体中也是如此。咖啡对血管的影响是中性的,这可能是因为习惯性饮用咖啡对血压没有明显影响。
{"title":"Habitual Regular Coffee Consumption and Arterial Stiffness: Data From the 3rd Pamela Survey.","authors":"Raffaella Dell'Oro, Fosca Quarti-Trevano, Rita Facchetti, Cesare Cuspidi, Giuseppe Mancia, Guido Grassi","doi":"10.1093/ajh/hpae072","DOIUrl":"10.1093/ajh/hpae072","url":null,"abstract":"<p><strong>Background: </strong>We evaluated whether chronic coffee consumption affects arterial stiffness, assessed by cardio-ankle vascular index (CAVI).</p><p><strong>Methods: </strong>In 514 subjects, aged 66.6 ± 9.9 years (mean ± SD), recruited in the 3rd follow-up of the PAMELA study, subdivided into 3 groups according to the daily intake of regular coffee (0, 1-2, and ≥3 cups/day), we measured CAVI and clinic, ambulatory blood pressure (BP), and other variables.</p><p><strong>Results: </strong>The 3 groups displayed similar age, gender, metabolic, and renal profile. Clinic and ambulatory BPs were similar in the 3 groups, this being the case for CAVI (0 cup: 9.1 ± 1.8, 1-2 cups: 9.5 ± 2.3, and ≥3 cups: 9.2 ± 2.1 m/s, P = NS). No significant gender difference in CAVI and in participants under antihypertensive treatment was detected.</p><p><strong>Conclusions: </strong>Our data show that chronic coffee consumption leaves unaffected arterial stiffness in the general population, this being the case in subgroups. The neutral vascular impact of coffee may favor the absence of any significant BP effect of habitual coffee intake.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"755-758"},"PeriodicalIF":3.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Aldosteronism and Kidney Hemodynamics: Adding Another Piece to the Puzzle. 原发性醛固酮增多症与肾脏血液动力学:拼图中的另一块拼图。
IF 3.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-16 DOI: 10.1093/ajh/hpae084
Gregory L Hundemer, Mohsen Agharazii
{"title":"Primary Aldosteronism and Kidney Hemodynamics: Adding Another Piece to the Puzzle.","authors":"Gregory L Hundemer, Mohsen Agharazii","doi":"10.1093/ajh/hpae084","DOIUrl":"10.1093/ajh/hpae084","url":null,"abstract":"","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"748-750"},"PeriodicalIF":3.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum Myostatin is Associated With Central-to-Peripheral Arterial Stiffness Gradient in Healthy Adolescents: The MACISTE Study. 血清肌生长激素与健康青少年从中央到外周的动脉僵化梯度有关。MACISTE研究。
IF 3.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-16 DOI: 10.1093/ajh/hpae089
R Curcio, L Nunziangeli, E Nulli Migliola, F Battista, M D'Abbondanza, F Anastasio, M E Crapa, L Sanesi, G Pucci, G Vaudo

Background: Myostatin is a protein compound, structurally related to the transforming growth factor-beta protein, which plays a pivotal role in regulating muscle growth and extracellular matrix production. It exerts both profibrotic and antihypertrophic effects on vascular smooth muscle cells. Aim of the study was to explore the potential association between serum myostatin levels (sMSTN) and carotid-femoral pulse wave velocity (cf-PWV), carotid-radial pulse wave velocity (cr-PWV), and their ratio (PWVr), in a cohort of healthy adolescents.

Methods: A cohort of 128 healthy subjects (mean age 17 ± 2 years, 59% male) was randomly selected from participants to the MACISTE (Metabolic And Cardiovascular Investigation at School, TErni) study. sMSTN was assessed utilizing an enzyme-linked immunosorbent assay. PWVs were measured in the supine position using high-fidelity applanation tonometry.

Results: The mean cf-PWV was 5.1 ± 0.9 m/s, cr-PWV was 6.9 ± 0.9 m/s, and PWVr was 0.75 ± 0.12. PWVr exhibited a linear increase across increasing quartiles of sMSTN (0.71 ± 0.1, 0.74 ± 0.1, 0.7 ± 0.1, 0.77 ± 0.1, P for trend = 0.03), whereas the association between sMSTN and each single component of PWVr (cf-PWV, cr-PWV) did not attain statistical significance. Quartiles of sMSTN displayed a positive trend with serum HDL-cholesterol (P = 0.01) and a negative one with LDL-cholesterol (P = 0.01). In a multivariate linear model, the association between PWVr and sMSTN was independent of SBP values, age, sex, heart rate, BMI, HDL-cholesterol, and HOMA Index.

Conclusions: In healthy adolescents, sMSTN showed independent associations with PWVr, a measure of central-to-peripheral arterial stiffness gradient. sMSTN may exert differential effects on the structural and functional properties of the arterial wall.

背景:肌生长因子是一种在结构上与 TGF-beta 蛋白相关的蛋白质化合物,在调节肌肉生长和细胞外基质生成方面起着关键作用。 肌生长因子对血管平滑肌细胞具有促破坏和抗肥厚作用。本研究旨在探讨健康青少年队列中血清肌生长激素水平(sMSTN)与颈动脉-股动脉脉搏波速度(cf-PWV)、颈动脉-桡动脉脉搏波速度(cr-PWV)及其比值(PWVr)之间的潜在关联。方法:从 MACISTE(Metabolic And Cardiovascular Investigation at School, TErni)研究的参与者中随机抽取了 128 名健康受试者(平均年龄为 17±2岁,59%为男性)。采用高保真眼压计测量仰卧位时的脉搏波速度:结果:平均 cf-PWV 为 5.1±0.9 m/s,cr-PWV 为 6.9±0.9 m/s,PWVr 为 0.75±0.12。随着 sMSTN 四分位数的增加,脉搏波速度呈线性增加(0.71±0.1、0.74±0.1、0.7±0.1、0.77±0.1,趋势 p=0.03),而 sMSTN 与脉搏波速度的每个单项成分(cf-PWV、cr-PWV)之间的关系未达到统计学意义。sMSTN 的四分位数与血清高密度脂蛋白胆固醇呈正相关趋势(p=0.01),与低密度脂蛋白胆固醇呈负相关趋势(p=0.01)。在多变量线性模型中,脉搏波速度与 sMSTN 之间的关系与 SBP 值、年龄、性别、心率、体重指数、高密度脂蛋白胆固醇和 HOMA 指数无关:sMSTN可能对动脉壁的结构和功能特性产生不同的影响。
{"title":"Serum Myostatin is Associated With Central-to-Peripheral Arterial Stiffness Gradient in Healthy Adolescents: The MACISTE Study.","authors":"R Curcio, L Nunziangeli, E Nulli Migliola, F Battista, M D'Abbondanza, F Anastasio, M E Crapa, L Sanesi, G Pucci, G Vaudo","doi":"10.1093/ajh/hpae089","DOIUrl":"10.1093/ajh/hpae089","url":null,"abstract":"<p><strong>Background: </strong>Myostatin is a protein compound, structurally related to the transforming growth factor-beta protein, which plays a pivotal role in regulating muscle growth and extracellular matrix production. It exerts both profibrotic and antihypertrophic effects on vascular smooth muscle cells. Aim of the study was to explore the potential association between serum myostatin levels (sMSTN) and carotid-femoral pulse wave velocity (cf-PWV), carotid-radial pulse wave velocity (cr-PWV), and their ratio (PWVr), in a cohort of healthy adolescents.</p><p><strong>Methods: </strong>A cohort of 128 healthy subjects (mean age 17 ± 2 years, 59% male) was randomly selected from participants to the MACISTE (Metabolic And Cardiovascular Investigation at School, TErni) study. sMSTN was assessed utilizing an enzyme-linked immunosorbent assay. PWVs were measured in the supine position using high-fidelity applanation tonometry.</p><p><strong>Results: </strong>The mean cf-PWV was 5.1 ± 0.9 m/s, cr-PWV was 6.9 ± 0.9 m/s, and PWVr was 0.75 ± 0.12. PWVr exhibited a linear increase across increasing quartiles of sMSTN (0.71 ± 0.1, 0.74 ± 0.1, 0.7 ± 0.1, 0.77 ± 0.1, P for trend = 0.03), whereas the association between sMSTN and each single component of PWVr (cf-PWV, cr-PWV) did not attain statistical significance. Quartiles of sMSTN displayed a positive trend with serum HDL-cholesterol (P = 0.01) and a negative one with LDL-cholesterol (P = 0.01). In a multivariate linear model, the association between PWVr and sMSTN was independent of SBP values, age, sex, heart rate, BMI, HDL-cholesterol, and HOMA Index.</p><p><strong>Conclusions: </strong>In healthy adolescents, sMSTN showed independent associations with PWVr, a measure of central-to-peripheral arterial stiffness gradient. sMSTN may exert differential effects on the structural and functional properties of the arterial wall.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"777-783"},"PeriodicalIF":3.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141625656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Therapeutic Drug Monitoring on Adherence and Blood Pressure: A Multicenter Randomized Clinical Trial. 药物监测对依从性和血压的影响:多中心随机临床试验。
IF 3.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-16 DOI: 10.1093/ajh/hpae059
Lene V Halvorsen, Camilla L Søraas, Anne Cecilie K Larstorp, Ulla Hjørnholm, Vibeke N Kjær, Knut Liestøl, Arleen Aune, Eirik Olsen, Karl Marius Brobak, Ola U Bergland, Stine Rognstad, Nikolai R Aarskog, Sondre Heimark, Fadl Elmula M Fadl Elmula, Eva Gerdts, Rune Mo, Marit D Solbu, Mimi S Opdal, Sverre E Kjeldsen, Morten Rostrup, Aud Høieggen

Background: Drug concentration in blood or urine is an acknowledged method to detect nonadherence. Observational studies suggest that informing patients about low or absent serum drug levels improves blood pressure (BP). We performed a multicenter randomized clinical trial to test the hypothesis that therapeutic drug monitoring (TDM) could improve drug adherence and BP in patients with uncontrolled hypertension (HT).

Methods: Patients were ≥18 years on stable treatment with at least 2 antihypertensive agents. We planned to randomize 80 nonadherent patients with a systolic daytime ambulatory BP ≥135 mm Hg to TDM intervention or not. The control group and the study personnel who measured BP remained uninformed about serum drug measurements throughout. All patients and physicians were blinded for BPs. Lifestyle advice and detailed information on the disease process and the importance of BP treatment were given to both groups.

Results: From 2017 to 2022, we randomized 46 diagnosed nonadherent from a total of 606 patients with uncontrolled HT. The TDM group had a 6.7 (±14.5) mm Hg reduction from 147.9 (±10.3) to 141.1 (±14.1) mm Hg, and the control group experienced a 7.3 (±13.2) mm Hg reduction from 147.1 (±9.2) to 139.1 (±17.4) mm Hg, P = 0.9 between groups. Adherence improved in both groups, 73% in the TDM group and 59% in the control group became adherent at 3 months, P = 0.51.

Conclusions: In our prospective multicenter clinical trial of uncontrolled and nonadherent hypertensive patients, we found no additional effect of TDM on BP and drug adherence compared with standard care.

Clinical trials registration: Trial Number NCT03209154, www.clinicaltrials.gov.

背景:血液或尿液中的药物浓度是一种公认的检测不依从性的方法。观察性研究表明,告知患者血清药物浓度偏低或缺失可改善血压(BP)。我们进行了一项多中心随机临床试验,以验证治疗药物监测(TDM)可改善未控制高血压患者的服药依从性和血压的假设:患者年龄≥18 岁,正在接受至少两种降压药物的稳定治疗。我们计划将 80 名日间非卧床血压(ABPM)收缩压≥135 mmHg 的非依从性患者随机分为 TDM 干预组和非 TDM 干预组。对照组和测量血压的研究人员自始至终对血清药物测量结果一无所知。所有患者和医生都对血压进行了盲测。两组患者均获得了生活方式建议以及关于疾病过程和血压治疗重要性的详细信息:从 2017 年到 2022 年,我们从总共 606 名未控制的高血压患者中随机抽取了 46 名确诊的非依从患者。TDM组从147.9(±10.3)毫米汞柱降至141.1(±14.1)毫米汞柱,降幅为6.7(±14.5)毫米汞柱;对照组从147.1(±9.2)毫米汞柱降至139.1(±17.4)毫米汞柱,降幅为7.3(±13.2)毫米汞柱,组间P=0.9。两组患者的依从性都有所改善,三个月后,TDM 组 73% 的患者和对照组 59% 的患者都能依从治疗,P=0.51:在我们对未控制和未坚持服药的高血压患者进行的前瞻性多中心临床试验中,我们发现与标准护理相比,治疗药物监测(TDM)对血压和服药依从性没有额外影响。
{"title":"Effect of Therapeutic Drug Monitoring on Adherence and Blood Pressure: A Multicenter Randomized Clinical Trial.","authors":"Lene V Halvorsen, Camilla L Søraas, Anne Cecilie K Larstorp, Ulla Hjørnholm, Vibeke N Kjær, Knut Liestøl, Arleen Aune, Eirik Olsen, Karl Marius Brobak, Ola U Bergland, Stine Rognstad, Nikolai R Aarskog, Sondre Heimark, Fadl Elmula M Fadl Elmula, Eva Gerdts, Rune Mo, Marit D Solbu, Mimi S Opdal, Sverre E Kjeldsen, Morten Rostrup, Aud Høieggen","doi":"10.1093/ajh/hpae059","DOIUrl":"10.1093/ajh/hpae059","url":null,"abstract":"<p><strong>Background: </strong>Drug concentration in blood or urine is an acknowledged method to detect nonadherence. Observational studies suggest that informing patients about low or absent serum drug levels improves blood pressure (BP). We performed a multicenter randomized clinical trial to test the hypothesis that therapeutic drug monitoring (TDM) could improve drug adherence and BP in patients with uncontrolled hypertension (HT).</p><p><strong>Methods: </strong>Patients were ≥18 years on stable treatment with at least 2 antihypertensive agents. We planned to randomize 80 nonadherent patients with a systolic daytime ambulatory BP ≥135 mm Hg to TDM intervention or not. The control group and the study personnel who measured BP remained uninformed about serum drug measurements throughout. All patients and physicians were blinded for BPs. Lifestyle advice and detailed information on the disease process and the importance of BP treatment were given to both groups.</p><p><strong>Results: </strong>From 2017 to 2022, we randomized 46 diagnosed nonadherent from a total of 606 patients with uncontrolled HT. The TDM group had a 6.7 (±14.5) mm Hg reduction from 147.9 (±10.3) to 141.1 (±14.1) mm Hg, and the control group experienced a 7.3 (±13.2) mm Hg reduction from 147.1 (±9.2) to 139.1 (±17.4) mm Hg, P = 0.9 between groups. Adherence improved in both groups, 73% in the TDM group and 59% in the control group became adherent at 3 months, P = 0.51.</p><p><strong>Conclusions: </strong>In our prospective multicenter clinical trial of uncontrolled and nonadherent hypertensive patients, we found no additional effect of TDM on BP and drug adherence compared with standard care.</p><p><strong>Clinical trials registration: </strong>Trial Number NCT03209154, www.clinicaltrials.gov.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"826-836"},"PeriodicalIF":3.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11403020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140848743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Size Dimension Chart for Reference Cuff Validation and Limitations in Current Recommendations. 用于验证参考袖带的尺寸规格表和现行建议的局限性。
IF 3.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-16 DOI: 10.1093/ajh/hpae061
Stephen P Juraschek

Background: International standards used for device validation protocols require that the reference cuff conforms to a width and length that is 37 to 50% and 75 to 100% of the arm circumference, respectively. However, there is no published chart of appropriate width and length dimensions across the range of arm circumferences. The objective of this report was to create a chart that could be used to guide reference cuff selection and compare recommended dimensions with two common cuff systems.

Methods: Arm circumferences, ranging from 22 to 52 cm were used to create a reference table for width and length requirements. Arm circumferences were grouped following the American Heart Association (AHA) recommendation for cuff sizes. Cuff dimension data was extracted from the website of a cuff system commonly used for validations (the Baum Corporation). Both the AHA recommendations and Baum sizes were compared with the recommended reference dimensions.

Results: There were discrepancies in size naming conventions between the Baum Corporation and the AHA cuff systems. Moreover, there were gaps in both systems where the cuff would not be recommended for validation (31-32 cm for Baum and 30-31 cm for the AHA). Neither system had cuffs that could be used for the largest arm circumferences.

Conclusions: This chart highlights the need for more than one cuff system in validation studies and the critical need for cuffs that could be used for validation among larger arm circumferences.

背景:用于设备验证协议的国际标准要求参考袖带的宽度和长度分别符合臂围的 37% 至 50% 和 75% 至 100% 的范围。然而,目前还没有关于臂围范围内适当宽度和长度尺寸的公开图表。我们的目标是创建一个图表,用于指导参考袖带的选择,并比较两种常见袖带系统的推荐尺寸:方法:使用从 22 厘米到 52 厘米不等的臂围创建一个宽度和长度要求参考表。臂围按照美国心脏协会推荐的袖带尺寸进行分组。从常用于验证的袖带系统(鲍姆公司)的网站上提取袖带尺寸数据,并将美国心脏协会的建议和鲍姆公司的尺寸与建议的参考尺寸进行比较:结果:鲍姆公司和美国心脏协会袖带系统的尺寸命名规则存在差异。此外,两个系统中都存在不建议验证的袖带间隙(鲍姆公司为 31-32 厘米,美国心脏协会为 30-31 厘米)。两个系统都没有可用于最大臂围的袖带:我们的图表突出表明,在验证研究中需要不止一种袖带系统,而且亟需可用于验证臂围较大者的袖带。
{"title":"Size Dimension Chart for Reference Cuff Validation and Limitations in Current Recommendations.","authors":"Stephen P Juraschek","doi":"10.1093/ajh/hpae061","DOIUrl":"10.1093/ajh/hpae061","url":null,"abstract":"<p><strong>Background: </strong>International standards used for device validation protocols require that the reference cuff conforms to a width and length that is 37 to 50% and 75 to 100% of the arm circumference, respectively. However, there is no published chart of appropriate width and length dimensions across the range of arm circumferences. The objective of this report was to create a chart that could be used to guide reference cuff selection and compare recommended dimensions with two common cuff systems.</p><p><strong>Methods: </strong>Arm circumferences, ranging from 22 to 52 cm were used to create a reference table for width and length requirements. Arm circumferences were grouped following the American Heart Association (AHA) recommendation for cuff sizes. Cuff dimension data was extracted from the website of a cuff system commonly used for validations (the Baum Corporation). Both the AHA recommendations and Baum sizes were compared with the recommended reference dimensions.</p><p><strong>Results: </strong>There were discrepancies in size naming conventions between the Baum Corporation and the AHA cuff systems. Moreover, there were gaps in both systems where the cuff would not be recommended for validation (31-32 cm for Baum and 30-31 cm for the AHA). Neither system had cuffs that could be used for the largest arm circumferences.</p><p><strong>Conclusions: </strong>This chart highlights the need for more than one cuff system in validation studies and the critical need for cuffs that could be used for validation among larger arm circumferences.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"751-754"},"PeriodicalIF":3.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140896871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Drug Monitoring and the Challenge of Conducting Trials to Improve Antihypertensive Medication Adherence. 治疗药物监测与开展改善降压药物依从性试验的挑战。
IF 3.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-16 DOI: 10.1093/ajh/hpae075
Paul Muntner, Rikki M Tanner
{"title":"Therapeutic Drug Monitoring and the Challenge of Conducting Trials to Improve Antihypertensive Medication Adherence.","authors":"Paul Muntner, Rikki M Tanner","doi":"10.1093/ajh/hpae075","DOIUrl":"10.1093/ajh/hpae075","url":null,"abstract":"","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"745-747"},"PeriodicalIF":3.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11403019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Participation of Ferroptosis in Fibrosis of the Heart and Kidney Tissues in Dahl Salt-Sensitive Hypertensive Rats. 铁蛋白沉积参与了达尔盐敏感性高血压大鼠心脏和肾脏组织的纤维化。
IF 3.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-16 DOI: 10.1093/ajh/hpae076
Ya-Qi Huang, Kuang Peng, Jun Yan, Hui-Lin Chen, Pei-Yong Jiang, Ya-Fang Du, Xiang Ling, Si-Liang Zhang, Jie Wu

Background: Salt-sensitive hypertension is often more prone to induce damage to target organs such as the heart and kidneys. Abundant recent studies have demonstrated a close association between ferroptosis and cardiovascular diseases. Therefore, we hypothesize that ferroptosis may be closely associated with organ damage in salt-sensitive hypertension. This study aimed to investigate whether ferroptosis is involved in the occurrence and development of myocardial fibrosis and renal fibrosis in salt-sensitive hypertensive rats.

Methods: Ten 7-week-old male Dahl salt-sensitive (Dahl-SS) rats were adaptively fed for 1 week, then randomly divided into two groups and fed either a normal diet (0.3% NaCl, normal diet group) or a high-salt diet (8% NaCl, high-salt diet group) for 8 weeks. Blood pressure of the rats was observed, and analysis of the hearts and kidneys of Dahl-SS rats was conducted via hematoxylin-eosin (HE) staining, Masson staining, Prussian blue staining, transmission electron microscopy, tissue iron content detection, malondialdehyde content detection, immunofluorescence, and Western blot.

Results: Compared to the normal diet group, rats in the high-salt diet group had increases in systolic blood pressure and diastolic blood pressure (P < 0.05); collagen fiber accumulation was observed in the heart and kidney tissues (P < 0.01), accompanied by alterations in mitochondrial ultrastructure, reduced mitochondrial volume, and increased density of the mitochondrial double membrane. Additionally, there were significant increases in both iron content and malondialdehyde levels (P < 0.05). Immunofluorescence and Western blot results both indicated significant downregulation (P < 0.05) of xCT and GPX4 proteins associated with ferroptosis in the high-salt diet group.

Conclusions: Ferroptosis is involved in the damage and fibrosis of the heart and kidney tissues in salt-sensitive hypertensive rats.

背景:盐敏感性高血压通常更容易诱发心脏和肾脏等靶器官的损伤。因此,我们推测铁蛋白沉积与盐敏感性高血压的器官损伤密切相关。本研究旨在探讨铁蛋白沉积是否参与盐敏感性高血压大鼠心肌纤维化和肾脏纤维化的发生和发展:方法:10 只 7 周大的雄性 Dahl 盐敏感(Dahl-SS)大鼠适应性喂养 1 周,然后随机分为两组,分别喂养正常饮食(0.3% NaCl,NDS 组)或高盐饮食(8% NaCl,HDS 组)8 周。观察大鼠的血压,并通过 HE 染色、Masson 染色、普鲁士蓝染色、TEM、组织铁含量检测、MDA 含量检测、免疫荧光和 Western 印迹对 Dahl-SS 大鼠的心脏和肾脏进行分析:结果:与 NDS 组大鼠相比,HDS 组大鼠收缩压(SBP)和舒张压(DBP)均升高(PC结论:铁色素沉着参与了大鼠心血管疾病的发生:铁蛋白沉积参与了盐敏感性高血压大鼠心脏和肾脏组织的损伤和纤维化。
{"title":"The Participation of Ferroptosis in Fibrosis of the Heart and Kidney Tissues in Dahl Salt-Sensitive Hypertensive Rats.","authors":"Ya-Qi Huang, Kuang Peng, Jun Yan, Hui-Lin Chen, Pei-Yong Jiang, Ya-Fang Du, Xiang Ling, Si-Liang Zhang, Jie Wu","doi":"10.1093/ajh/hpae076","DOIUrl":"10.1093/ajh/hpae076","url":null,"abstract":"<p><strong>Background: </strong>Salt-sensitive hypertension is often more prone to induce damage to target organs such as the heart and kidneys. Abundant recent studies have demonstrated a close association between ferroptosis and cardiovascular diseases. Therefore, we hypothesize that ferroptosis may be closely associated with organ damage in salt-sensitive hypertension. This study aimed to investigate whether ferroptosis is involved in the occurrence and development of myocardial fibrosis and renal fibrosis in salt-sensitive hypertensive rats.</p><p><strong>Methods: </strong>Ten 7-week-old male Dahl salt-sensitive (Dahl-SS) rats were adaptively fed for 1 week, then randomly divided into two groups and fed either a normal diet (0.3% NaCl, normal diet group) or a high-salt diet (8% NaCl, high-salt diet group) for 8 weeks. Blood pressure of the rats was observed, and analysis of the hearts and kidneys of Dahl-SS rats was conducted via hematoxylin-eosin (HE) staining, Masson staining, Prussian blue staining, transmission electron microscopy, tissue iron content detection, malondialdehyde content detection, immunofluorescence, and Western blot.</p><p><strong>Results: </strong>Compared to the normal diet group, rats in the high-salt diet group had increases in systolic blood pressure and diastolic blood pressure (P < 0.05); collagen fiber accumulation was observed in the heart and kidney tissues (P < 0.01), accompanied by alterations in mitochondrial ultrastructure, reduced mitochondrial volume, and increased density of the mitochondrial double membrane. Additionally, there were significant increases in both iron content and malondialdehyde levels (P < 0.05). Immunofluorescence and Western blot results both indicated significant downregulation (P < 0.05) of xCT and GPX4 proteins associated with ferroptosis in the high-salt diet group.</p><p><strong>Conclusions: </strong>Ferroptosis is involved in the damage and fibrosis of the heart and kidney tissues in salt-sensitive hypertensive rats.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"784-791"},"PeriodicalIF":3.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141292947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of the Anaphylatoxin Receptor C5aR2 in Angiotensin II-Induced Hypertension and Hypertensive End-Organ Damage. 无乳毒素受体 C5aR2 在血管紧张素 II 诱导的高血压和高血压终末器官损伤中的作用
IF 3.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-16 DOI: 10.1093/ajh/hpae082
Leonie Dreher, Marlies Bode, Nicolas Ehnert, Catherine Meyer-Schwesinger, Thorsten Wiech, Jörg Köhl, Tobias B Huber, Tilo Freiwald, Georg R Herrnstadt, Ulrich O Wenzel

Backround: Complement activation may facilitate hypertension through its effects on immune responses. The anaphylatoxin C5a, a major inflammatory effector, binds to the C5a receptors 1 and 2 (C5aR1, C5aR2). We have recently shown that C5aR1-/- mice have reduced hypertensive renal injury. The role of C5aR2 in hypertension is unknown.

Methods: For examination of C5aR2 expression on infiltrating and resident renal cells a tandem dye Tomato-C5aR2 knock-in reporter mouse was used. Human C5aR2 expression was analyzed in a single-cell RNAseq data set from the kidneys of hypertensive patients. Finally, we examined the effect of angiotensin II-induced hypertension in C5aR2-deficient mice.

Results: Flow cytometric analysis of leukocytes isolated from kidneys of the reporter mice showed that dendritic cells are the major C5aR2-expressing population (34%) followed by monocyte/macrophages (30%) and neutrophils (14%). Using confocal microscopy C5aR2 was not detected in resident renal or cardiac cells. In the human kidney, C5aR2 was also mainly found in monocytes, macrophages, and dendritic cells with a significantly higher expression in hypertension (P < 0.05). Unilateral nephrectomy was performed followed by infusion of Ang II (0.75 ng/g/min) and a high salt diet in wildtype (n = 18) and C5aR2-deficient mice (n = 14). Blood pressure, renal injury (albuminuria, glomerular filtration rate, glomerular and tubulointerstitial injury, inflammation), and cardiac injury (cardiac fibrosis, heart weight, gene expression) did not differ between hypertensive wildtype and C5aR2-/- mice.

Conclusions: In summary, C5aR2 is mainly expressed in myeloid cells in the kidney in mice and humans but its deficiency has no effect on Ang II-induced hypertensive injury.

背景:补体激活可通过对免疫反应的影响促进高血压。C5a是一种主要的炎症效应物质,可与C5a受体1和2(C5aR1、C5aR2)结合。我们最近发现,C5aR1-/-小鼠的高血压肾损伤有所减轻。C5aR2在高血压中的作用尚不清楚:方法:使用串联染料 Tomato-C5aR2 基因敲入报告小鼠来检测 C5aR2 在浸润和驻留肾细胞中的表达。在高血压患者肾脏的单细胞 RNAseq 数据集中分析了人类 C5aR2 的表达。最后,我们研究了 C5aR2 基因缺陷小鼠对 Ang II 诱导的高血压的影响:从报告小鼠肾脏分离的白细胞流式细胞分析显示,树突状细胞是主要的 C5aR2 表达群体(34%),其次是单核/巨噬细胞(30%)和中性粒细胞(14%)。使用共聚焦显微镜在常驻肾脏或心脏细胞中未检测到 C5aR2。在人类肾脏中,C5aR2 也主要存在于单核细胞、巨噬细胞和树突状细胞中,在高血压中的表达量明显更高(pConclusion):总之,C5aR2 主要在小鼠和人类肾脏的髓样细胞中表达,但其缺乏对 Ang II 诱导的高血压损伤没有影响。
{"title":"Role of the Anaphylatoxin Receptor C5aR2 in Angiotensin II-Induced Hypertension and Hypertensive End-Organ Damage.","authors":"Leonie Dreher, Marlies Bode, Nicolas Ehnert, Catherine Meyer-Schwesinger, Thorsten Wiech, Jörg Köhl, Tobias B Huber, Tilo Freiwald, Georg R Herrnstadt, Ulrich O Wenzel","doi":"10.1093/ajh/hpae082","DOIUrl":"10.1093/ajh/hpae082","url":null,"abstract":"<p><strong>Backround: </strong>Complement activation may facilitate hypertension through its effects on immune responses. The anaphylatoxin C5a, a major inflammatory effector, binds to the C5a receptors 1 and 2 (C5aR1, C5aR2). We have recently shown that C5aR1-/- mice have reduced hypertensive renal injury. The role of C5aR2 in hypertension is unknown.</p><p><strong>Methods: </strong>For examination of C5aR2 expression on infiltrating and resident renal cells a tandem dye Tomato-C5aR2 knock-in reporter mouse was used. Human C5aR2 expression was analyzed in a single-cell RNAseq data set from the kidneys of hypertensive patients. Finally, we examined the effect of angiotensin II-induced hypertension in C5aR2-deficient mice.</p><p><strong>Results: </strong>Flow cytometric analysis of leukocytes isolated from kidneys of the reporter mice showed that dendritic cells are the major C5aR2-expressing population (34%) followed by monocyte/macrophages (30%) and neutrophils (14%). Using confocal microscopy C5aR2 was not detected in resident renal or cardiac cells. In the human kidney, C5aR2 was also mainly found in monocytes, macrophages, and dendritic cells with a significantly higher expression in hypertension (P < 0.05). Unilateral nephrectomy was performed followed by infusion of Ang II (0.75 ng/g/min) and a high salt diet in wildtype (n = 18) and C5aR2-deficient mice (n = 14). Blood pressure, renal injury (albuminuria, glomerular filtration rate, glomerular and tubulointerstitial injury, inflammation), and cardiac injury (cardiac fibrosis, heart weight, gene expression) did not differ between hypertensive wildtype and C5aR2-/- mice.</p><p><strong>Conclusions: </strong>In summary, C5aR2 is mainly expressed in myeloid cells in the kidney in mice and humans but its deficiency has no effect on Ang II-induced hypertensive injury.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"810-825"},"PeriodicalIF":3.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American Journal of Hypertension
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1